Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720599 · ClinicalTrials.gov registry record
Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy
A clinical trial, sponsored by Exosome Diagnostics.
- Completed
- Registry status
- 120
- Enrollment target
NCT04720599: Completed study, sponsored by Exosome Diagnostics.
NCT04720599 is a clinical trial that has completed, run by Exosome Diagnostics. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04720599 has completed, sponsored by Exosome Diagnostics.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a European Union Launch.
Interventions
- DIAGNOSTIC_TEST ExoDx Prostate(IntelliScore)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-06-01 |
What the finished NCT04720599 record still lists
NCT04720599 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which ExoDx Prostate(IntelliScore) is the first listed.
NCT04720599 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04720599 about?
NCT04720599 is a clinical study titled "Clinical Evaluation of ExoDx Prostate(IntelliScore) in Men Presenting for Initial Prostate Biopsy". The study described here is being conducted to prospectively confirm the performance of the ExoDx Prostate gene expression assay in patients presenting for an initial prostate biopsy and support of CE-marking the test for a European Union Launch.
What is the current status of trial NCT04720599?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2020-06-01. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT04720599?
The interventions under investigation include: ExoDx Prostate(IntelliScore) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04720599?
This trial is sponsored by Exosome Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI